AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET

Company Participants

Jessica Ekeberg - Director, IR

Jim Corbett - CEO

David O'Toole - CFO

Conference Call Participants

Brooks O'Neil - Lake Street Capital Markets

Ross Osborne - Cantor Fitzgerald

Ryan Zimmerman - BTIG

Chris Kallos - MSTF

Madeleine Williams - Wilsons

Lyanne Harrison - Bank of America

Operator

Good day and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker today, Jessica Ekeberg, Director of Investor Relations.

Jessica Ekeberg

Thank you, operator. Welcome to AVITA Medical's fourth quarter and full year 2023 earnings call.

Joining me on today's call are Jim Corbett, Chief Executive Officer; and David O'Toole, Chief Financial Officer.

Today's earnings release is available on our website, www.avitamedical.com under the Investor Relations section.

Before we begin, let me remind you that this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties that could cause actual results to differ materially from any expectations expressed or implied by the forward-looking statements.

Please review our most recent filings with the SEC, specifically the risk factors described within the Form 10-K for the year ended December 31st, 2023, for additional information. Any forward-looking statements provided during this call are based on management's expectations as of today.

I will now turn the call over to Jim for his comments.

Jim Corbett

Thank you, Jessica. Good afternoon and thank you for joining us today. I will begin today's call by discussing our financial and business highlights of the fourth quarter and full year 2023, followed by an update on our priorities for 2024. Following this update, I will turn the call over to David, who will provide commentary on our 2023 financial performance and the 2024 guidance before opening the call to Q&A.

During the February 2023 conference call, I outlined our 2023 priorities, our growth strategy and committed to providing quarterly and annual guidance. Additionally, I emphasized that 2023 would mark a significant turning point for AVITA Medical, a year in which we plan to transform our business by in multiple new indications, dramatically increase our growth trajectory. I'm pleased to report we did just that.